Zoetis Q2 2026: Flat Revenue, Muted EPS Persist as OA Headwinds Linger

What happened

Zoetis reported Q2 2026 revenue of $2.5 billion, flat year-over-year and down 1% on an organic operational basis, extending a prolonged stagnation. Net income slipped 5% to $691 million, though diluted EPS inched up 1% to $1.65 as cost controls and share buybacks cushioned the bottom line. The results underscore the ongoing drag from the osteoarthritis monoclonal antibody franchise, where U.S. Librela volumes remain under pressure from safety concerns, offsetting robust Simparica and dermatology growth. Livestock performance also remained choppy, with portfolio pruning and macroeconomic softness weighing on the segment, consistent with earlier guidance cuts. Management's ability to hold EPS steady through cost discipline is commendable but does not yet signal a return to the mid-teens growth investors once expected.

Implication

The Q2 2026 stagnation reinforces that Zoetis's premium valuation isn't justified by current growth. While cost control is protecting EPS, without a recovery in its high-margin OA franchise, revenue growth is likely to remain in low-single digits. The company's heavy reliance on a few key products increases vulnerability if competitive pressures intensify. Until Librela prescription trends stabilize or new pipeline successes materialize, the stock may continue to trade sideways or drift lower. A more constructive entry point would be closer to the $110 level identified in the deep value analysis, offering a wider margin of safety.

Thesis delta

The Q2 2026 print confirms persistent OA franchise weakness and no organic reacceleration, reinforcing the WAIT stance from the prior deep value report. Without clear catalysts for growth improvement, the risk/reward at current levels remains unattractive, and a more compelling entry would require a lower price or tangible OA stabilization.